IMAB - I-MAB Filed 2022 Annual Report on Form 20-F

PR Newswire

GAITHERSBURG, Md. and SHANGHAI , May 1, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has filed its annual report on Form 20-F for the year ended December 31, 2022 with the U.S. Securities and Exchange Commission ("SEC") on May 1, 2023 .

The annual report is available on the Company's investor relations website at ir.i-mabbiopharma.com and on the SEC's website at www.sec.gov . The Company will provide hard copies of the annual report, free of charge, to its shareholders and ADS holders upon written request. Requests should be directed to Investor Relations, I-Mab, 55th Floor, New Bund Center, 555 West Haiyang Road, Pudong District, Shanghai , 200124, People's Republic of China .

About I-Mab

I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon, commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-Proof-of-Concept and Fast-to-Market development strategies through internal R&D and global partnerships and commercial partnerships. I-Mab as established its global footprint in Shanghai , Beijing , Hangzhou , Lishui and Hong Kong in China , and Maryland and San Diego in the United States . For more information, please visit http://www.i-mabbiopharma.com and follow I-Mab on LinkedIn , Twitter , and WeChat .

For more information, please contact:

I-Mab Contacts

SOURCE I-Mab